Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Ovarian Neoplasms 7Neoplasms 6Fallopian Tube Neoplasms 6Neoplasm Metastasis 5Carcinoma 4Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Hemangiosarcoma 2Glioblastoma 2Gastrointestinal Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Oligodendroglioma 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1

Interventions

Temozolomide 74Radiotherapy 34Carboplatin 21Bevacizumab 18Magnetic Resonance Spectroscopy 17Irinotecan 16Carmustine 16Vincristine 14Surgical Procedures, Operative 13Filgrastim 13Procarbazine 10Erlotinib Hydrochloride 8Cyclophosphamide 8Peripheral Blood Stem Cell Transplantation 7O(6)-benzylguanine 7Lomustine 7Etoposide 7sargramostim 6Imatinib Mesylate 6Flucytosine 6Cisplatin 62-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 6temsirolimus 5Vorinostat 5Thiotepa 5Radiotherapy, Intensity-Modulated 5Radiation 5Immunohistochemistry 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × trebananib × Clear all
NCT01609790 2022-07-21

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

National Cancer Institute (NCI)

Phase 2 Completed
137 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡